News | July 24, 2009

IABPs Aid Survival Rates in Patients With AMI Cardiogenic Shock

July 24, 2009 – The 30-day survival improved in patients with acute myocardial infarction complicated by cardiogenic shock who were treated with intra-aortic balloon pump (IABP) counterpulsation, according to a new study in the American Journal of Cardiology (vol. 104, issue 3, pages 327-332, August 2009).

Although IABPs are increasingly being used for the treatment of patients with cardiogenic shock from acute myocardial infarction, there is little data on the long-term outcomes. Researchers at the Thoraxcenter, Erasmus Medical Center in Rotterdam, The Netherlands, and the Department of Intensive Care Medicine, Academic Medical Center, Amsterdam, The Netherlands, evaluated the 30-day and long-term mortality and to identify predictors for 30-day and long-term all-cause mortality of patients with AMI complicated by cardiogenic shock who were treated with an IABP.

From January 1990 to June 2004, 300 consecutive patients treated with IABP were included. The mean age of the study population was 61 ± 11 years, and 79 percent of the patients were men. The survival rate until IABP removal after successful hemodynamic stabilization was 70 percent (n = 211). The overall cumulative 30-day survival rate was 58 percent. The 30-day mortality rate decreased over time from 52 percent in 1990 to 1994 to 36 percent in 2000 to 2004. Follow-up ranged from zero to 15 years. In patients who survived until IABP removal, the cumulative 1-, 5-, and 10-year survival rate was 69, 58 and 36 percent, respectively. The adjusted predictors of long-term mortality were arrhythmias during the intensive cardiac care unit stay (hazard ratio [HR] 1.8, 95 percent confidence interval [CI] 1.2 to 2.9) and renal failure during the intensive cardiac care unit stay (HR 2.5, 95 percent CI 1.3 to 5.1). After adjustment, treatment with primary percutaneous coronary intervention (HR 0.5, 95 percent CI 0.3 to 0.9) and coronary artery bypass grafting (HR 0.4, 95 percent CI 0.2 to 0.8) were associated with lower long-term mortality.

For more information:

Related Content

Getinge Issues Worldwide Voluntary Correction of Maquet/Getinge Cardiosave Intra-Aortic Balloon Pump
News | Intra-Aortic Balloon Pumps (IABP) | September 24, 2018
September 24, 2018 — Getinge is voluntarily initiating a worldwide recall involving a field correction of approximate
Maquet Datascope Corp. is recalling the CardioSave Hybrid Intra-aortic Balloon Pump (IABP).

The touchscreen Maquet Datascope CardioSave Hybrid Intra-aortic Balloon Pump (IABP) system console.

News | Intra-Aortic Balloon Pumps (IABP) | June 06, 2018
June 6, 2018 — Maquet Datascope Corp.
An example of an intra-aortic balloon pump (IABP) from Maquet. The results of the SEMPER FI trial. #europcr2018 #Europcr

An example of an intra-aortic balloon pump (IABP) from Maquet. 

Feature | Intra-Aortic Balloon Pumps (IABP) | May 31, 2018
May 31, 2018 — The results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia
FDA Clears Teleflex Arrow AC3 Optimus Intra-Aortic Balloon Pump (IABP)
Technology | Intra-Aortic Balloon Pumps (IABP) | May 02, 2017
May 2, 2017 — The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Teleflex Inc.
Impella CP heart pump, TCT 2016, intra-aortic balloon counterpulsation, IABP, clinical study
News | Intra-Aortic Balloon Pumps (IABP) | January 03, 2017 | Dave Fornell
The Impella CP heart pump (Abiomed) demonstrated no improvement in mortality for patients with myocardial infarction...
Teleflex, Arrow IAB catheter, intra-aortic balloon pump, worldwide recall
News | Intra-Aortic Balloon Pumps (IABP) | March 11, 2016
Teleflex Inc. announced the worldwide recall of Arrow International intra-aortic balloon catheter kits and percutaneous...
Overlay Init